

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Nektar Therapeutics	10/08/2008
RECEIVING PARTY DATA	
Name:	Stamford Devices Limited
Street Address:	Galway Business Park
City:	Dangan, Galway
State/Country:	IRELAND
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	6921020
CORRESPONDENCE DATA	
Fax Number:	(617)502-5002
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Phone:	617 248 5000
Email:	patentdocket@choate.com
Correspondent Name:	C. Hunter Baker, M.D., Ph.D., J.D.
Address Line 1:	Choate Hall & Stewart LLP
Address Line 2:	Two International Place - Suite 34
Address Line 4:	Boston, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	2008506-0010
NAME OF SUBMITTER:	C. Hunter Baker, M.D., Ph.D., J.D.
Total Attachments: 3	
source=Confirmation of Assignment#page1.tif	
source=Confirmation of Assignment#page2.tif	
source=Confirmation of Assignment#page3.tif	

OP \$40.00 6921020

CONFIRMATION OF ASSIGNMENT

This Confirmation of Assignment is being entered into by and between **Nektar Therapeutics (“Nektar”)**, a corporation organized under the laws of the state of Delaware, having its principal place of business at 201 Industrial Road, San Carlos, California, and **Stamford Devices Limited (“Stamford”)**, a limited company organized under the laws of Ireland, having its principal place of business at Galway Business Park, Dangan, Galway, Ireland.

WHEREAS Aerogen, Inc. (“Aerogen”), having its place of business at 201 Industrial Road, San Carlos, California, is a subsidiary of Nektar;

WHEREAS Aerogen is owner of the patents and patent applications listed in Schedule A (collectively, the “Patents”); and

WHEREAS Nektar entered into a License Agreement dated November of 2007 in which Nektar assigned Aerogen’s entire right, title, and interest in the Patents to Stamford (“Assignee”), subject to any terms and conditions associated therewith.

NOW THEREFORE, pursuant to such Agreement and in consideration of the sum of One U.S. Dollar (\$1.00) paid by Assignee to Assignor (the receipt of which Assignor hereby acknowledges), Assignor hereby assigns and transfers to Assignee Assignor’s right, title and interest in said inventions and the Patents, and any and all patent or patents in the United States of America and all foreign countries which may be granted therefor and thereon, and in and to any and all divisions, continuations, and continuations-in-part of the Patents, or reissues, reexaminations, or extensions of the Patents, and all rights under all applicable intellectual property treaties and conventions, and the full benefits thereof, and all rights, privileges and advantages appertaining thereto, including any and all rights of Assignor to damages, profits or recoveries of any nature for past infringement of the Patents, and the payment of any and all maintenance fees, taxes, and the like, to hold the same unto and to the use of Assignee, its successors and assigns during the residue of the respective terms for which the Patents were or will be granted and during any such terms, and for any and all rights extending from said divisions, continuations, continuations-in-part, reissues, reexaminations, and extensions.

AND for the same consideration, Assignor hereby covenants and agrees to and with Assignee, its successors, legal representatives and assigns that Assignor will, at the cost and expense of the Assignee, sign all papers and documents, take all lawful oaths, and do all acts necessary or required to be done for the recordation of this assignment of the Patents to Assignee.

AND Assignor hereby requests the Director of the United States Patent and Trademark Office to issue, to Assignee, any and all Patents of the United States arising from such United States patents and patent applications included in the Patents for the use and behalf of the Assignee, its successors, legal representatives, and assigns.

Executed at SAN CARLOS, CA this 8th day of OCTOBER, 2008.

Nektar Therapeutics

By: *Gil M Labrucherie*

Name: GIL M LABRUCHERIE

Title: GENERAL COUNSEL

Witness:

Michael J. Meyer
Name:

10/8/08
Date

Witness:

Vanya M. Fache
Name:

10/8/08
Date

SCHEDULE A
Assigned Patent Rights

Patent/Application Number	Filing Date
6,014,970	June 11, 1998
6,205,999	September 8, 1998
6,814,071	July 22, 2002
6,921,020	March 21, 2003
6,546,927	March 13, 2001
11/215,886	August 30, 2005

4366193v1